Eisai Acquires European Rights to Prialt, Severe Chronic Pain Agent Prialt, from Elan.Tokyo, Japan, Feb 10, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Eisai and Irish Elan Corporation, plc. of Ireland announced February 9 the conclusion of an agreement for Eisai's strategic product acquisition in Europe of Elan's non-opioid severe chronic pain agent Prialt (ziconotide acetate). Eisai will obtain development, manufacturing and marketing rights for Prialt for the European region from Elan. This agreement will come into force on receipt of the necessary approvals from relevant regulatory authorities and the satisfaction of other standard closing conditions. Prialt is a peptide which is the synthetic equivalent of a peptide found in a marine snail. It suppresses pain by selectively blocking N-type calcium channels on nerves. In December 2004, the US FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approved Prialt for the management of severe, chronic pain in patients who require intrathecal intrathecal /in·tra·the·cal/ (-the´k'l) within a sheath; through the theca of the spinal cord into the subarachnoid space. Intrathecal analgesia analgesia /an·al·ge·sia/ (an?al-je´ze-ah) 1. absence of sensibility to pain. 2. the relief of pain without loss of consciousness. . Prialt has been awarded an orphan drug orphan drug, drug developed under the U.S. Orphan Drug Act (1983) to treat a disease that affects fewer than 200,000 people in the United States. The orphan drug law offers tax breaks and a seven-year monopoly on drug sales to induce companies to undertake the status in the European Union European Union (EU), name given since the ratification (Nov., 1993) of the Treaty of European Union, or Maastricht Treaty, to the European Community , and was granted a Marketing Authorization through the European Union's Centralized Procedure in February 2005. Prialt is the first medicine that was approved in Europe as a non-opioid, intrathecal, severe chronic pain agent. Based on this strategic product acquisition, Eisai aims to expand the range of products and expand the business territory in Europe. The company believes that Prialt will meet the needs of patients with severe chronic pain in Europe and contribute to increase their benefits. Eisai will create a foothold in the company's emerging oncology and critical care franchise. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion